18 results about "Parathyroid Tetany" patented technology

The invention discloses an RGD-click chemical crosslinking siRNA nano-carrier, a preparation method thereof and application of the nano-carrier in preparation of a medicine for treating secondary thyroidism, and belongs to the technical field of medicines.The nano-carrier is RGD-PEG-PLys (N), and the preparation method of the nano-carrier comprises the steps of synthesis of PLys (ss-DBCO), synthesis of RGD-PEG-PLys (N) and the like. According to the application, the nano-carrier is used for preparing siRNA composite nanoparticles; vascular endothelial targeting (RGD), dynamic stability (click crosslinking) and microenvironment responsiveness (disulfide bond) are organically combined for the first time to achieve mutual synergistic interaction, and the effect ceiling of an existing material is broken through; according to the siRNA composite nanoparticle, the silence effect of the PTH gene as long as 70 days can be achieved through single intravenous injection, the PTH inhibition rate is larger than 85%, the siRNA accumulation amount in parathyroid gland tissue is remarkably increased through RGD targeting (8.6 times that of a non-targeting group), the liver and kidney distribution amount is reduced by 60%, and the system toxicity is controllable.

A local positioning system (LPS) is provided. The LPS includes at least three local position tracking devices, each further including one or more of: a clock synchronized to the clock in each of the other devices; a transmitter transmitting signals over time synchronized to the clock; and a receiver receiving the signals over time from the other devices. The LPS further includes a processor operatively coupled to at least one of the devices and that is configured to: obtain for each of the signals a location of the device that transmitted that signal; produce one or more representations of at least a part of a living body based on at least one of one or more of the locations and one or more further representations of the at least the part of the living body, each of the representations including one or more temporal frames; and to provide output.

This invention discloses a parathyroid tissue transplantation device, belonging to the field of transplantation device technology, including a syringe, a cutting device, and a pusher. The cutting device has the same size as the inner wall of the syringe, and a through groove runs through the top surface of the cutting device. A material hopper is installed in the through groove, and the bottom surface of the material hopper is equipped with dense blades. A squeezing rod is placed in the material hopper, and a pusher plate is fixed at one end of the squeezing rod. The pusher plate has the same size as the inner wall of the material hopper. A drive component is installed inside the cutting device, which controls the rotation of the cutting blades. By setting up the syringe, cutting device, and pusher, the parathyroid tissue can be efficiently processed into a homogenate, realizing seamless linkage of tissue loading, cutting, and pushing. The entire process is completed in a closed structure, reducing tissue exposure, contamination, and residual loss. It realizes an integrated operation of immediate harvesting, processing, and transplantation during surgery, greatly improving the operation efficiency, standardization, and tissue survival rate of parathyroid tissue transplantation, and reducing the risk of postoperative hypoparathyroidism.

The invention provides a PTH1R agonist compound, a pharmaceutical composition and application of the PTH1R agonist compound. The compound has good PTH1R agonist activity and is used for treating diseases and / or diseases related to parathyroid hypofunction and / or osteoporosis and preparing drugs for the diseases and / or diseases.

The invention discloses a cinacalcet-containing transdermal patch as well as a preparation method and application thereof. The transdermal patch comprises a high-molecular matrix layer, wherein the high-molecular matrix layer comprises cinacalcet, a silicone pressure-sensitive adhesive and one or more high-molecular polymers selected from a water-insoluble cellulose derivative, polyvinylpyrrolidone and a polyethylene caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer. The transdermal patch disclosed by the invention is good in drug permeability and colloid application performance, high in safety, free of skin irritation, high in stability and good in uniformity, and can meet the requirements of clinically treating hyperparathyroidism or hypercalcemia.

Pharmaceutical compositions of polymeric micelle cinacalcet suitable for intravenous or intraperitoneal administration, and methods of making and use thereof in the treatment of various diseases and disorders, such as hyperparathyroidism and hypercalcemia, are provided.

The invention belongs to the technical field of chemical raw material medicines, and particularly relates to an aryl alkyl amine compound as well as a preparation method and application thereof. The structure of the aryl alkyl amine compound is shown as a formula I. Experiments prove that the allosteric agonist effect of the compound provided by the invention on a calcium-sensitive receptor is superior to or equivalent to that of Evocalpet, and the aryl alkyl amine compound has potential in preparation of drugs for treating secondary hyperparathyroidism. Formula I

A tissue detection system includes a light source configured to illuminate tissue of interest. An imaging head including a detector is configured to acquire auto-fluorescence of the illuminated target tissue of interest responsive to the application of the light and generate one or more auto-fluorescence images of the target tissue of interest. A controller is configured to regulate operational control of the imaging head when acquiring, receiving, and processing images. If an intensity signal of the detected one or more auto-fluorescence images of the target tissue of interest leads to a determination of parathyroid tissue, the detector is configured to acquire laser speckle contrast images to determine the amount of perfusion of the target tissue of interest to distinguish well perfused parathyroid tissue having a low speckle contrast image from less perfused tissue having a high speckle contrast image. The less perfused tissue is identified a potential false positive.

The invention relates to the technical field of medical instruments, in particular to a grinding suction device for parathyroid gland autotransplantation, which comprises a needle tube and a needle head which are communicated with each other, and is characterized in that a piston assembly is arranged in the needle tube, a grinding assembly is arranged at the top of the needle tube, the outer side of the grinding assembly is symmetrically communicated with a conveying assembly, and one side of the grinding assembly is communicated with a suspension assembly; the grinding assembly comprises a sleeve and a grinding rod, a grinding head is fixedly connected to the bottom of the grinding rod, the bottom of the sleeve is fixedly connected with the top of the needle tube, a driving assembly is slidably connected into the sleeve and sleeves the grinding rod, the grinding head is located on the movement track of the driving assembly, and the bottom of the grinding head is fixedly connected with the piston assembly. The grinding assembly, the conveying assembly, the suspension assembly, the needle tube and the piston assembly are integrated, coherent operation from grinding to transplanting of parathyroid gland tissue is achieved, and the problems that in a traditional mode, tissue grinding is insufficient, a needle head is prone to being blocked, and operation is tedious are solved.

The application provides a camera equipment for an electric knife, and belongs to the technical field of auxiliary camera equipment for electric knives, and comprises an electric knife provided with a binocular depth camera and a processor. The processor acquires a synchronous video stream through the binocular depth camera, and recognizes a recurrent laryngeal nerve and parathyroid region and boundary points thereof by using a pre-trained neural network, and then constructs three-dimensional coordinates of the boundary points with the end of the electric knife as the origin. The system continuously tracks the movement of the boundary points, and predicts the future positions by analyzing the historical trajectories. If the boundary point closest to the electric knife in the predicted points exceeds a safety threshold, the system will issue a real-time warning. The equipment can dynamically identify and predict the movement of key tissues, and assist the doctor to actively avoid intraoperative risks.

The invention discloses a parathyroid gland autologous implantation device, and relates to the technical field of parathyroid gland autologous implantation, and the parathyroid gland autologous implantation device comprises a double-cavity injector body; the combined module is arranged at the top end of the double-cavity injector body and comprises an air compression cavity and a rotary chopping cavity, an air pressure piston and a partitioning guide groove are movably connected into the air compression cavity, the air pressure piston is located above the partitioning guide groove, one end of the air pressure piston is located in the air compression cavity, and the other end of the air pressure piston is located in the rotary chopping cavity. The interior of the rotary chopping cavity is movably connected with a mincing cutter; and an adjusting module. According to the parathyroid gland autoimplantation device, the injector type handheld device is adopted, the human engineering design is met, the switching use design of the rotary chopping cavity and the air compression cavity integrates the two operation requirements, the operation process is simplified, use is convenient and fast, the treatment difficulty is reduced, the error rate is reduced, and the treatment efficiency is improved. And meanwhile, the modular design has the effects of reliability and safety.

The application relates to a parathyroid real-time detection method based on Anchor-Free and space-time consistency. An Anchor-Free base convolutional neural network and a feature pyramid model are used to perform feature extraction on a detection image to generate a pyramid multi-scale feature map group, then a shared detection head is used to obtain a plurality of scale corresponding classification confidence maps, a center confidence map and a target frame regression map, and then the classification confidence map and the center confidence map are multiplied to obtain a center classification confidence map. A space-time classification memory map is constructed, information is extracted by using the center confidence map, a time sequence classification result map is generated, and the time sequence classification result map and the center confidence map are fused to generate a final classification confidence map. The application enhances the detection effect and the adaptability of the detection network, and alleviates the target drift problem of the detector under complex conditions such as shielding, fog and illumination when the parathyroid is encountered.

The invention is applicable to the technical field of hyperspectral imaging and medical treatment, and provides a parathyroid gland operation detection device and method based on spectral microscopy-risk early warning. An eyepiece group; the imaging spectrometer is used for collecting a hyperspectral image of the to-be-detected tissue; the electric control adjustable light splitting system is used for splitting the optical signal output by the microscopic imaging system to the eyepiece group and the imaging spectrometer and adaptively adjusting the light intensity split to the eyepiece group and the imaging spectrometer; the dye-free near-infrared imaging unit is used for collecting an autofluorescence signal of the tissue to be detected; the parathyroid gland recognition module is used for performing weighted fusion on the hyperspectral image and the autofluorescence signal and recognizing parathyroid gland tissues according to a weighted fusion result; and the operation risk early warning unit is used for identifying the blood vessel based on the hemoglobin characteristic peak in the hyperspectral image and triggering an alarm when the operation instrument approaches the blood vessel. The precision and safety of parathyroid gland surgery can be remarkably improved.

Methods for treating vitamin D insufficiency and secondary hyperparathyroidism in patients having CKD comprising administering repeat doses of 25-hydroxyvitamin D are disclosed. The methods comprise administering 25-hydroxyvitamin D in an amount effective to safely raise the patient's serum 25-hydroxyvitamin D level to greater than 90 ng / ml and / or to control the patient's serum ratio of 25-hydroxyvitamin D to 24,25-dihydroxyvitamin D to less than 20.

The invention relates to a parathyroid gland fluorescence image segmentation method based on deep learning, and the method comprises the steps: carrying out the wavelet decomposition of a first image, so as to obtain sub-images of different frequency bands, designing a dual-path network on the basis of U-net, and achieving the segmentation of parathyroid glands in the sub-images, and finally, realizing the fusion of the sub-images by using wavelet inverse transformation to obtain a second image in which the parathyroid gland is accurately segmented. According to the method, a plurality of sub-band images of different frequency bands are decomposed through wavelet transform, so that the neural network can analyze frequency spectrum information of the sub-band images of different frequency bands, and the parathyroid gland segmentation accuracy is improved; the method designs a dual-path network, realizes complementary enhancement of global semantics and local features on the basis of frequency domain decomposition, high-frequency sub-image processing effectively inhibits noise interference, low-frequency sub-image processing retains organization structure information, and improves the accuracy of parathyroid gland region segmentation through cross-path feature interaction.

A combined auto-fluorescence imaging and laser speckle contrast imaging (LSCI) system to enable intra-operative parathyroid identification and viability assessment with the same tool. The system includes a light source for emitting a beam of light to illuminate a target of interest, and an imaging head positioned over the target of interest for individually acquiring auto-fluorescence images and LSCI images of light from the illuminated target of interest responsive to the illumination. Auto-fluorescence imaging helps identify the parathyroid, while LSCI helps assess its viability.

One embodiment provides a tightly targeted minimally invasive therapy (TTMIT) parathyroid tissue ablating instrument. A substance that cytotoxically ablates parathyroidal tissue during application in the parathyroidal tissue of therapeutically sufficient units of an electromagnetic energy having a frequency only ranging from ultraviolet to visible to near infrared. A substance delivery device is configured to introduce the substance into the parathyroidal tissue. An electromagnetic energy treatment device is configured to apply the therapeutically sufficient units of the electromagnetic energy within a thermal range that is non-cytotoxic to the parathyroidal tissue to the substance after the substance has been introduced by the substance delivery device. A sensor is configured to monitor activation of the substance as the therapeutically sufficient units of the electromagnetic energy are applied. The electromagnetic energy treatment device is further configured to modulate applying the therapeutically sufficient units of the electromagnetic energy once the substance has been activated.

The present application relates to the use of a PTH compound for the treatment of chronic parathyroidism wherein said treatment comprises the step of administering a weekly dose of a PTH compound per week to a patient suffering from chronic parathyroidism, and wherein before the start of the treatment, the PTH compound is added to the patient. Patients are clinically determined to no longer rely on active vitamin D and calcium supplements to maintain serum within a normal range; and related aspects.